IGF2BP2 and prostate carcinoma: Biochemical studies further confirmed that IGF2BPs, including IGF2BP2, stabilize m6A-modified RNAs across various cellular, physiological, and pathological settings, including human cancer cells such as hepatocellular carcinoma (HepG2), cervical cancer (HeLa), prostate cancer (22Rv1), and acute myeloid leukemia.